Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ziltivekimab for arterial wall inflammation in atherosclerosis
NL-OMON53495Phase 2Recruiting
- Sponsor
- Department of Vascular Medicine of the Academic Medical Center
- Start
- Nov 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised trial in atherosclerosis and coronary arteriosclerosis comparing Ziltivekimab with Placebo (2 arms). Primary endpoint: Mean percentage change in coronary artery inflammation and monocyte activation at 20 weeks. Started Nov 2023; status: recruiting.
02
Drugs
ziltivekimab
03
Conditions
atherosclerosiscoronary arteriosclerosis
Beyond the preview
Go deeper on NL-OMON53495.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON53495.